Phase I trial of irinotecan and amrubicin with granulocyte colony-stimulating factor support in extensive-stage small-cell lung cancer
Tóm tắt
We conducted a phase I trial of irinotecan (CPT-11), a topoisomerase I inhibitor, combined with amrubicin, a topoisomerase II inhibitor, with recombinant human granulocyte colony-stimulating factor (rhG-CSF) support to overcome the neutropenia associated with this particular combination. The aim was to determine the maximum tolerated dose (MTD) of amrubicin combined with a fixed dose of CPT-11 and the dose-limiting toxicities (DLTs) of this combination in extensive-stage small-cell lung cancer (ED-SCLC) patients. Fifteen patients with ED-SCLC were treated at 3-week intervals with amrubicin on days 1–3 plus 60 mg/m2 CPT-11 on days 1 and 8. In addition, prophylactic rhG-CSF (50 μg/m2) was given from day 4 to day 21, except on the day of CPT-11 administration. Amrubicin was started at 30 mg/m2 and then escalated in 5 mg/m2 increments until MTD was reached. The MTD of amrubicin was 35 mg/m2, since 2 of 4 patients experienced DLTs during the first cycle of treatment at the 40 mg/m2 dose level. Neutropenia, neutropenic fever, ileus, and diarrhea were the DLTs. There were 13 partial responses among the 13 assessable patients, yielding an overall response rate of 100 %. Median progression-free survival and overall survival were 7.4 months and 13.4 months, respectively. The combination of amrubicin and CPT-11 showed high activity against ED-SCLC with acceptable toxicity. Use of rhG-CSF allowed the dose of amrubicin to be raised 40 % above that in the original regimen (60 mg/m2 CPT-11 and 25 mg/m2 amrubicin).
Tài liệu tham khảo
citation_journal_title=Chest; citation_title=Granulocyte colony-stimulating factor or neutrophil-induced pulmonary toxicity: myth or reality? Systematic review of clinical case reports and experimental data; citation_author=E Azoulay, H Attalah, A Harf, B Schlemmer, C Delclaux; citation_volume=120; citation_publication_date=2001; citation_pages=1695-1701; citation_doi=10.1378/chest.120.5.1695; citation_id=CR1
citation_journal_title=Ann Oncol; citation_title=Irinotecan in the treatment of gastric cancer; citation_author=R Bugat; citation_volume=14; citation_issue=Suppl 2; citation_publication_date=2003; citation_pages=ii37-ii40; citation_id=CR2
citation_journal_title=Pharmacoeconomics; citation_title=Granulocyte colony–stimulating factor for chemotherapy-induced neutropenia in patients with small cell lung cancer: the 40% rule revisited; citation_author=EA Calhoun, GT Schumock, JM McKoy, S Pickard, KA Fitzner, EA Heckinger, EF Powell, KR McCaffrey, CL Bennett; citation_volume=23; citation_publication_date=2005; citation_pages=767-775; citation_doi=10.2165/00019053-200523080-00003; citation_id=CR3
citation_journal_title=Adv Med Sci; citation_title=New strategies for targeting the therapy of NSCLC: the role of ERCC1 and TS; citation_author=P Ceppi, M Papotti, G Scagliotti; citation_volume=55; citation_publication_date=2010; citation_pages=22-25; citation_doi=10.2478/v10039-010-0017-4; citation_id=CR4
citation_journal_title=Eur J Cancer; citation_title=New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1); citation_author=EA Eisenhauer, P Therasse, J Bogaerts, LH Schwartz, D Sargent, R Ford, J Dancey, S Arbuck, S Gwyther, M Mooney, L Rubinstein, L Shankar, L Dodd, R Kaplan, D Lacombe, J Verweij; citation_volume=45; citation_publication_date=2009; citation_pages=228-247; citation_doi=10.1016/j.ejca.2008.10.026; citation_id=CR5
citation_journal_title=Cancer; citation_title=The emerging role of irinotecan (CPT-11) in the treatment of malignant glioma in brain tumors; citation_author=HS Friedman, ST Keir, PJ Houghton; citation_volume=97; citation_publication_date=2003; citation_pages=2359-2362; citation_doi=10.1002/cncr.11305; citation_id=CR6
citation_journal_title=Cancer Chemother Pharmacol; citation_title=Genetic linkage of UGT1A7 and UGT1A9 polymorphisms to UGT1A1*6 is associated with reduced activity for SN-38 in Japanese patients with cancer; citation_author=K Fujita, Y Ando, F Nagashima, W Yamamoto, H Eodo, K Araki, K Kodama, T Miya, M Narabayashi, Y Sasaki; citation_volume=60; citation_publication_date=2007; citation_pages=515-522; citation_doi=10.1007/s00280-006-0396-1; citation_id=CR7
citation_journal_title=Oncology (Williston Park); citation_title=Lung cancer management in 2010; citation_author=AK Ganti, CH Huang, MA Klein, S Keefe, MJ Kelley; citation_volume=25; citation_publication_date=2011; citation_pages=64-73; citation_id=CR8
citation_journal_title=Oncology (Williston Park); citation_title=Current concepts in the diagnosis and management of small-cell lung cancer; citation_author=AK Ganti, WW West, RP Lackner, A Kessinger; citation_volume=24; citation_publication_date=2010; citation_pages=1034-1039; citation_id=CR9
citation_journal_title=J Hematother Stem Cell Res; citation_title=Fatal pulmonary toxicity related to the administration of granulocyte colony-stimulating factor in amyloidosis: a report and review of growth factor-induced pulmonary toxicity; citation_author=MA Gertz, MQ Lacy, J Bjornsson, MR Litzow; citation_volume=9; citation_publication_date=2000; citation_pages=635-643; citation_doi=10.1089/15258160050196678; citation_id=CR10
citation_journal_title=J Org Chem; citation_title=Stereospecific total synthesis of 9-aminoanthracyclines: (+)-9-amino-9-deoxydaunomycin and related compounds; citation_author=K Ishizumi, N Ohashi, N Tanno; citation_volume=52; citation_publication_date=1987; citation_pages=4477-4485; citation_doi=10.1021/jo00229a010; citation_id=CR11
citation_journal_title=Ann Hematol; citation_title=Development of interstitial pneumonitis during treatment with granulocyte colony-stimulating factor; citation_author=M Katoh, K Shikoshi, M Takada, M Umeda, T Tsukahara, S Kitagawa, T Shirai; citation_volume=67; citation_publication_date=1993; citation_pages=201-202; citation_doi=10.1007/BF01695869; citation_id=CR12
citation_journal_title=Cancer chemother; citation_title=[Clinical trial of KRN 8601 in patients with neutropenia induced by chemotherapy for lung cancer]. Gan to kagaku ryoho; citation_author=I Kimura, T Ohonoshi, T Okabe, F Takaku, H Nishiwaki, N Saijo, H Ikegami, M Fukuoka, K Furuse; citation_volume=17; citation_publication_date=1990; citation_pages=999-1003; citation_id=CR13
citation_journal_title=Am J Respir Crit Care Med; citation_title=Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control study; citation_author=S Kudoh, H Kato, Y Nishiwaki, M Fukuoka, K Nakata, Y Ichinose, M Tsuboi, S Yokota, K Nakagawa, M Suga, H Jiang, Y Itoh, A Armour, C Watkins, T Higenbottam, F Nyberg; citation_volume=177; citation_publication_date=2008; citation_pages=1348-1357; citation_doi=10.1164/rccm.200710-1501OC; citation_id=CR14
citation_journal_title=Oncology (Huntingt); citation_title=The global role of irinotecan in the treatment of lung cancer: 2003 update; citation_author=CJ Langer; citation_volume=17; citation_publication_date=2003; citation_pages=30-40; citation_id=CR15
citation_journal_title=Clin Cancer Res; citation_title=Platinum resistance: the role of DNA repair pathways; citation_author=LP Martin, TC Hamilton, RJ Schilder; citation_volume=14; citation_publication_date=2008; citation_pages=1291-1295; citation_doi=10.1158/1078-0432.CCR-07-2238; citation_id=CR16
citation_journal_title=Br J Cancer; citation_title=A phase II trial of combination of CPT-11 and cisplatin for advanced non-small-cell lung cancer. CPT-11 Lung Cancer Study Group; citation_author=N Masuda, M Fukuoka, A Fujita, Y Kurita, S Tsuchiya, K Nagao, S Negoro, H Nishikawa, N Katakami, K Nakagawa, H Niitani; citation_volume=78; citation_publication_date=1998; citation_pages=251-256; citation_doi=10.1038/bjc.1998.473; citation_id=CR17
citation_journal_title=J Clin Oncol; citation_title=Phase I and pharmacologic study of irinotecan and etoposide with recombinant human granulocyte colony-stimulating factor support for advanced lung cancer; citation_author=N Masuda, M Fukuoka, S Kudoh, K Matsui, Y Kusunoki, M Takada, K Nakagawa, T Hirashima, H Tsukada, T Yana; citation_volume=12; citation_publication_date=1994; citation_pages=1833-1841; citation_id=CR18
citation_journal_title=J Clin Oncol; citation_title=CPT-11 in combination with cisplatin for advanced non-small-cell lung cancer; citation_author=N Masuda, M Fukuoka, M Takada, Y Kusunoki, S Negoro, K Matsui, S Kudoh, N Takifuji, K Nakagawa, S Kishimoto; citation_volume=10; citation_publication_date=1992; citation_pages=1775-1780; citation_id=CR19
citation_journal_title=Crit Rev Oncol Hematol; citation_title=Irinotecan (CPT-11): pharmacology and clinical applications; citation_author=N Masuda, S Kudoh, M Fukuoka; citation_volume=24; citation_publication_date=1996; citation_pages=3-26; citation_doi=10.1016/1040-8428(96)00201-6; citation_id=CR20
citation_journal_title=J Clin Oncol; citation_title=Combination of irinotecan and etoposide for treatment of refractory or relapsed small-cell lung cancer; citation_author=N Masuda, K Matsui, S Negoro, N Takifuji, K Takeda, T Yana, M Kobayashi, T Hirashima, Y Kusunoki, S Ushijima, I Kawase, T Tada, H Sawaguchi, M Fukuoka; citation_volume=16; citation_publication_date=1998; citation_pages=3329-3334; citation_id=CR21
citation_journal_title=J Natl Cancer Inst; citation_title=Phase I study of weekly intravenous infusions of CPT-11, a new derivative of camptothecin, in the treatment of advanced non-small-cell lung cancer; citation_author=S Negoro, M Fukuoka, N Masuda, M Takada, Y Kusunoki, K Matsui, N Takifuji, S Kudoh, H Niitani, T Taguchi; citation_volume=83; citation_publication_date=1991; citation_pages=1164-1168; citation_doi=10.1093/jnci/83.16.1164; citation_id=CR22
citation_journal_title=Br J Cancer; citation_title=Interstitial pneumonia in patients receiving granulocyte colony-stimulating factor during chemotherapy: survey in Japan 1991–96; citation_author=N Niitsu, S Iki, K Muroi, S Motomura, M Murakami, H Takeyama, A Ohsaka, A Urabe; citation_volume=76; citation_publication_date=1997; citation_pages=1661-1666; citation_doi=10.1038/bjc.1997.614; citation_id=CR23
citation_journal_title=J Clin Oncol; citation_title=Phase II trial of amrubicin for treatment of refractory or relapsed small-cell lung cancer: Thoracic Oncology Research Group Study 0301; citation_author=S Onoda, N Masuda, T Seto, K Eguchi, Y Takiguchi, H Isobe, H Okamoto, T Ogura, A Yokoyama, N Seki, Y Asaka-Amano, M Harada, A Tagawa, H Kunikane, M Yokoba, K Uematsu, T Kuriyama, Y Kuroiwa, K Watanabe; citation_volume=24; citation_publication_date=2006; citation_pages=5448-5453; citation_doi=10.1200/JCO.2006.08.4145; citation_id=CR24
citation_journal_title=Curr Oncol Rep; citation_title=Small cell lung cancer: past, present, and future; citation_author=E Rodriguez, RC Lilenbaum; citation_volume=12; citation_publication_date=2010; citation_pages=327-334; citation_doi=10.1007/s11912-010-0120-5; citation_id=CR25
citation_journal_title=Invest New Drugs; citation_title=Multicenter phase II study of amrubicin, 9-amino-anthracycline, in patients with advanced non-small-cell lung cancer (Study 1): West Japan Thoracic Oncology Group (WJTOG) trial; citation_author=T Sawa, T Yana, M Takada, T Sugiura, S Kudoh, T Kamei, T Isobe, H Yamamoto, S Yokota, N Katakami, Y Tohda, A Kawakami, Y Nakanishi, Y Ariyoshi; citation_volume=24; citation_publication_date=2006; citation_pages=151-158; citation_doi=10.1007/s10637-006-5937-2; citation_id=CR26
citation_journal_title=Biol Pharm Bull; citation_title=Efficacy of combination treatment and influence of schedule with irinotecan and amrubicin in human lung carcinoma cells in vivo and in vitro; citation_author=Y Shishido, T Furuta, T Matsuzaki, H Nagata, S Hashimoto; citation_volume=33; citation_publication_date=2010; citation_pages=1183-1191; citation_doi=10.1248/bpb.33.1183; citation_id=CR27
citation_journal_title=Br J Cancer; citation_title=Combined inhibition of topoisomerases I and II–is this a worthwhile/feasible strategy?; citation_author=PA Vasey, SB Kaye; citation_volume=76; citation_publication_date=1997; citation_pages=1395-1397; citation_doi=10.1038/bjc.1997.568; citation_id=CR28
citation_journal_title=Drug Des Devel Ther; citation_title=Next-generation anthracycline for the management of small cell lung cancer: focus on amrubicin; citation_author=M Yamamoto, A Takakura, N Masuda; citation_volume=2; citation_publication_date=2009; citation_pages=189-192; citation_id=CR29
citation_journal_title=Jpn J Cancer Res; citation_title=Cytotoxicity of amrubicin, a novel 9-aminoanthracycline, and its active metabolite amrubicinol on human tumor cells; citation_author=T Yamaoka, M Hanada, S Ichii, S Morisada, T Noguchi, Y Yanagi; citation_volume=89; citation_publication_date=1998; citation_pages=1067-1073; citation_doi=10.1111/j.1349-7006.1998.tb00498.x; citation_id=CR30
citation_journal_title=Invest New Drugs; citation_title=Phase II study of amrubicin in previously untreated patients with extensive-disease small cell lung cancer: West Japan Thoracic Oncology Group (WJTOG) study; citation_author=T Yana, S Negoro, M Takada, S Yokota, Y Takada, T Sugiura, H Yamamoto, T Sawa, M Kawahara, N Katakami, Y Ariyoshi, M Fukuoka; citation_volume=25; citation_publication_date=2007; citation_pages=253-258; citation_doi=10.1007/s10637-006-9012-9; citation_id=CR31
citation_journal_title=Cancer Chemother Pharmacol; citation_title=Phase I and pharmacologic study of irinotecan and amrubicin in advanced non-small cell lung cancer; citation_author=T Yanaihara, M Yokoba, S Onoda, M Yamamoto, S Ryuge, S Hagiri, M Katagiri, M Wada, H Mitsufuji, M Kubota, S Arai, H Kobayashi, N Yanase, T Abe, N Masuda; citation_volume=59; citation_publication_date=2007; citation_pages=419-427; citation_doi=10.1007/s00280-006-0279-5; citation_id=CR32